moxifloxacin has been researched along with ly-146032 in 12 studies
Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (ly-146032) | Trials (ly-146032) | Recent Studies (post-2010) (ly-146032) |
---|---|---|---|---|---|
3,157 | 552 | 1,690 | 122 | 1 | 35 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 10 (83.33) | 29.6817 |
2010's | 2 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
Frank, KL; Patel, R; Piper, KE; Reichert, EJ | 1 |
Cottagnoud, M; Cottagnoud, P; Schaffner, T; Stucki, A; Winkelmann, V | 1 |
Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
del Pozo, JL; Mandrekar, JN; Patel, R; Rouse, MS; Sampedro, MF; Steckelberg, JM | 1 |
Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Bowker, KE; Caspers, P; Gaucher, B; MacGowan, AP | 1 |
Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and ly-146032
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for moxifloxacin and ly-146032
Article | Year |
---|---|
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; DNA, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Nafcillin; Oxazolidinones; Penicillin-Binding Proteins; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus; Tetracycline | 2007 |
Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
Topics: Animals; Anti-Bacterial Agents; Bacteriolysis; Ceftriaxone; Cell Wall; Cerebrospinal Fluid; Choline; Daptomycin; Disease Models, Animal; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillin Resistance; Rabbits; Streptococcus pneumoniae; Treatment Outcome; Tritium | 2007 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
Topics: Anti-Infective Agents; Biofilms; Bioreactors; Electricity; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Staphylococcus epidermidis | 2009 |
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
Topics: Folic Acid Antagonists; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Phthalazines; Staphylococcus aureus; Streptococcus | 2009 |
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
Topics: Anti-Bacterial Agents; Aza Compounds; Biofilms; Clarithromycin; Daptomycin; Fluoroquinolones; Microscopy, Electron, Scanning; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Vancomycin | 2010 |